Polymersome-Based Drug Delivery Systems

Polymersomes are nanoscale vesicles formed by the self-assembly of amphiphilic block copolymers that encapsulate therapeutic agents within a central aqueous core or embed them in a stabilised polymer membrane. Their robust architecture and tunable membrane properties confer enhanced mechanical stability, prolonged circulation times and adjustable permeability compared with conventional lipid vesicles. By selecting appropriate hydrophilic-to-hydrophobic block ratios and incorporating degradable linkages or targeting ligands, polymersomes can be engineered to respond to pH, temperature, redox potential or external fields, enabling precise spatiotemporal control over cargo release. This versatility has spurred applications in oncology, central nervous system delivery, protein and nucleic acid therapeutics, imaging and combined therapeutic–diagnostic (theranostic) approaches. Key challenges remain in scaling up reproducible production, ensuring biocompatibility and biodegradation of constituent polymers, and navigating complex in vivo barriers such as the mononuclear phagocyte system and tissue-specific extravasation. Current efforts focus on optimising polymer chemistry for regulatory compliance, quantifying intracellular release kinetics and integrating multifunctional design features to accelerate the translation of polymersome platforms into safe and effective clinical nanomedicines.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Research from all publishers

Recent analyses of polymersome-based protein carriers have identified non-degradable polymer backbones and complex manufacturing protocols as major obstacles to clinical translation, prompting the development of biodegradable copolymers and streamlined assembly methods to improve batch-to-batch consistency and in vivo performance. Advances in cancer immunotherapy have harnessed the structural stability and surface functionalisation of polymersomes to co-deliver tumour antigens and immunomodulators, achieving enhanced dendritic cell activation and antitumour responses with precise spatiotemporal release profiles. A comprehensive review of self-assembled nanostructures places polymersomes alongside micelles and hydrogels, emphasising their superior cargo protection, stimuli-responsive discharge and the availability of FDA-approved polymers that could shorten regulatory pathways for novel therapeutic platforms.

Polymersome-Based Drug Delivery Systems publication trend

The graph below shows the total number of articles in polymersome-based drug delivery systems across all publications each year (not limited to Nature Index journals).

Technical terms

Polymersome: A vesicular structure formed by self-assembly of amphiphilic block copolymers, featuring a bilayer membrane and internal aqueous lumen for drug encapsulation.

Amphiphilic block copolymer: A macromolecule composed of covalently linked hydrophilic and hydrophobic polymer segments that drive self-assembly in aqueous environments.

Stimuli-responsive: The ability of a material to undergo reversible structural or physicochemical changes in response to environmental triggers such as pH, temperature or redox conditions.

Endocytosis: The cellular process by which cells internalise extracellular particles or vesicles through membrane invagination and vesicle formation.

Theranostic: A combined therapeutic and diagnostic approach in a single platform, enabling simultaneous treatment delivery and medical imaging or monitoring.

References

1. Polymersome-based protein drug delivery – quo vadis?. Chemical Society Reviews (2023).
2. Quantification of intracellular payload release from polymersome nanoparticles. Scientific Reports (2016).
3. Review of Contemporary Self-Assembled Systems for the Controlled Delivery of Therapeutics in Medicine. Nanomaterials (2021).
4. Polymersomes as a potential platform for cancer immunotherapy. Materials Today Advances (2022).